761 Main Avenue
37 articles with Owlstone Medical
5/23/2019Biopharma companies from across Europe share pipeline and strategy updates.
Owlstone Medical Enters into a Strategic Collaboration with Actelion to Develop a Breath-Based Test to Help Facilitate Early Detection of Pulmonary Hypertension
Owlstone Medical announces a strategic collaboration with Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & Johnson and a global leader in pulmonary arterial hypertension, to discover and validate a breath-based test to help facilitate the early diagnosis of pulmonary hypertension and its subtypes.
In addition to the planned BioNTech IPO, many other pharma and biotech companies in Europe, Asia and elsewhere shared news for the week.
University of Manchester and Owlstone Medical Partner on £250,000 Grant from Asthma UK and Innovate UK for Asthma Diagnostic Development
The University of Manchester, and Owlstone Medical announce the award of an Asthma UK/Innovate UK grant for theimprovement of asthma diagnosis.
Lots of interesting biotech news from Asia, Europe and elsewhere was reported this week. From tapeworms to using a breathalyzer test in lung cancer diagnostics, the global biotech industry is exploding with ideas.
Owlstone Medical Partners with Shanghai Renji Hospital to Pioneer Breath Biopsy Lung Cancer Trial in China
Owlstone Medical Ltd., a global diagnostics company developing a breathalyzer for applications in early disease detection and precision medicine, and Renji Hospital, announced a collaboration to conduct a clinical trial into the early detection of lung cancer with support from the Li Ka Shing Foundation.
Owlstone Medical today announces the appointment of Dr. Richard A Yost to its Scientific Advisory Board.
Investment will fund the global commercialization of Owlstone Medical’s Breath Biopsy® platform for early disease detection and precision medicine
Owlstone Medical Ltd. announced today the addition of Dr Andy Richards CBE to its Board as a Non-Executive Director.
It’s been a busy week for biopharma companies to name a chief executive officer. Over the past week, multiple companies have selected individuals to hold the top spots and guide the growth strategies of their companies.
Additions form a key strategic resource to advise on Breath Biopsy platform, product, and study development.
Owlstone Medical Provides Breath Biopsy Services to AstraZeneca to Study Disease Drivers in Asthma and COPD
Owlstone Medical announced it has signed a service agreement with AstraZeneca plc.
Owlstone Medical announced the launch of its Breath Biopsy® Kits, based on the company’s proprietary Breath Biopsy platform.
Owlstone Medical Raises $15 Million USD (£11 million GBP) To Drive Commercialization of Its Breath Biopsy Platform
Owlstone Medical Ltd. announced that it has raised $15 million (£11 million) to drive the global commercialization of its Breath Biopsy® platform.
SBRI Healthcare is delighted to congratulate Owlstone Medical on being named one of three winners of the global Idiopathic Pulmonary Fibrosis Catalyst Challenge.
Owlstone Medical today announced it is one of the three winners of the global Idiopathic Pulmonary Fibrosis (IPF) Catalyst Challenge, sharing the $1,000,000 (£720,000 GBP) award, each receiving $333,333 (£240,000 GBP).
Selected from a short list of nine finalists, out of hundreds of registrants, the winners were announced last night in Chicago as part of the final phase of the Challenge.
Owlstone Medical’s Breath Biopsy Platform Integrated Into GSK's Phase II Respiratory Disease Clinical Trial
Trial will analyze breath biomarkers to improve understanding of the treatment effects of a novel GSK pipeline drug candidate for COPD.
Owlstone Medical’s Disease Breathalyzer, ReCIVA, To Feature In Tomorrow’s World Gallery At The Science Museum, London
Owlstone Medical And Cancer Research UK (CRUK) Initiate Pan Cancer Clinical Trial To Evaluate Breath Biopsy For Early Detection Of Disease